ArticleAnnals of surgical oncology2026
Octogenarians Undergoing Pancreaticoduodenectomy versus Definitive Radiotherapy for Locoregional Therapy of Pancreatic Ductal Adenocarcinoma: A Nationwide Analysis.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreaticoduodenectomy (PD) remains the standard for locoregional therapy of pancreatic ductal adenocarcinoma (PDAC) in the head of the pancreas. However, even with optimal treatment, the prognosis for pancreatic cancer is poor, and octogenarians have a reduced life expectancy, thus potentially offsetting benefits of aggressive surgical intervention. The aim of this study was to compare survival outcomes with PD versus radiotherapy alone (dXRT) in octogenarians with non-metastatic PDAC.
methodsWe queried a national database to identify patients aged ≥80 years diagnosed with resectable or borderline-resectable PDAC in the head of the pancreas between 2004 and 2019. We performed a propensity score match to compare PD and dXRT.
resultsA total of 7910 patients were included in the analysis. The mean age was 83.1 ± 2.6 years, and 44.8% were male (n=3546) and 85.9% white (n=6795). The median survival of the overall cohort was 11.53 (interquartile range [IQR] 5.88-21.78) months. Among the matched cohort of 2982 patients, those who underwent PD had better median overall survival (OS; 14.65 [IQR 6.93-30.75] vs. 9.66 [IQR 5.72-15.87] months, p<0.001). In patients with early-stage (stage I and II) disease, PD was associated with a higher 5-year OS (13.03% vs. 2.07%, p<0.001). However, among patients with advanced-stage (stage III) disease, there was no difference in 5-year OS (4.67% vs. 2.02%, p=0.151).
conclusionsOctogenarians with non-metastatic PDAC have a poor long-term prognosis. Although PD is associated with a modest survival benefit in patients with early-stage disease, there is no associated survival benefit when compared with dXRT in patients with advanced-stage disease.
Indexed as
Identifiers
41559462What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.